Latest On CTI BioPharma Corp (CTIC):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-17 02:14 EST | News | CTI BioPharma: $1.7bn M&A With 85% Premium, Expect The Deal To Go Through | N/A |  |
| 2023-05-11 03:40 EST | News | CTI BioPharma Q1 2023 Earnings Preview | N/A | |
| 2023-05-10 14:37 EST | News | Swedish Orphan Biovitrum Ab to acquire CTI BioPharma for $9.10 per share | N/A | |
| 2023-04-21 19:28 EST | News | VONJO Keeps CTI BioPharma A Buy | N/A | |
| 2023-04-19 21:42 EST | News | Geron, CTI rally after leaked data for Legend Biotech’s blood cancer drug | N/A | |
| 2023-03-31 19:08 EST | News | CTI BioPharma: Q4, Missed Earnings, But Compelling Progress In Market Launch | N/A | |
| 2023-03-07 03:12 EST | News | CTI BioPharma Corp. (CTIC) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-07 03:12 EST | News | CTI BioPharma Corp. 2022 Q4 - Results - Earnings Call Presentation | N/A | |
| 2023-03-06 12:48 EST | News | CTI BioPharma GAAP EPS of -$0.14 misses by $0.05, revenue of $21.08M misses by $2.42M | N/A | |
| 2023-01-20 16:52 EST | News | CTI BioPharma: Limited Cash Runway, But Better Than Expected Commercial Launch | N/A | |
| 2023-01-12 21:09 EST | News | CTI BioPharma: Checking Back In | N/A | |
| 2022-11-09 04:25 EST | News | CTI Biopharma surges 17% higher on Q3 earnings beat | N/A | |
| 2022-11-08 10:31 EST | News | CTI BioPharma Corp. (CTIC) Q3 2022 Results - Earnings Call Transcript | N/A | |
| 2022-11-07 17:19 EST | News | CTI BioPharma GAAP EPS of -$0.13 beats by $0.03, revenue of $18.2M beats by $1.03M | N/A | |
| 2022-11-03 07:35 EST | News | CTI BioPharma's VONJO May Be Coming Of Age | N/A | |
| 2022-08-17 16:37 EST | News | CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch | N/A | |
| 2022-08-09 00:57 EST | News | CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M | N/A | |
| 2022-08-09 00:56 EST | News | CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-07-20 05:38 EST | News | CTI BioPharma: One Trick Pony Ready To Perform | N/A | |
| 2022-07-19 15:23 EST | News | CTI BioPharma: Approval Is Great, Now There's The Follow Through | N/A | |
| 2022-07-08 02:46 EST | News | CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis | N/A | |
| 2022-06-10 17:48 EST | News | CTI BioPharma slips after disclosing data for myelofibrosis therapy | N/A | |
| 2022-05-13 09:57 EST | News | CTI BioPharma GAAP EPS of -$0.37 beats by $0.04, revenue of $2.3M beats by $0.76M | N/A | |
| 2022-05-13 09:56 EST | News | CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-11 21:46 EST | News | CTI BioPharma Q1 2022 Earnings Preview | N/A | |
| 2022-05-05 01:52 EST | News | CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset | N/A | |
| 2022-04-11 04:28 EST | News | CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating | N/A | |
| 2022-04-01 04:52 EST | News | CTI BioPharma GAAP EPS of -$0.38 | N/A | |
| 2022-03-01 23:24 EST | News | CTI BioPharma surges on FDA approval for myelofibrosis therapy | N/A | |
| 2022-03-01 05:05 EST | News | CTI BioPharma: A Speculative Buy Into The PDUFA Date | N/A | |
| 2021-12-25 02:06 EST | News | CTI BioPharma: Long And Troubled History, Finally Approaching Approval | N/A | |
| 2021-12-01 20:10 EST | News | FDA delay on CTI myelofibrosis candidate creates buying opportunity, says Lake Street | N/A | |
| 2021-11-30 23:30 EST | News | BeyondSpring, CTI BioPharma gain ahead of FDA decision for key drugs | N/A | |
| 2021-11-30 23:28 EST | News | CTI BioPharma falls 13% in post market after FDA extends review of myelofibrosis drug | N/A | |
| 2021-11-30 02:39 EST | News | CTI BioPharma announces inducement grants to nine new employees under Nasdaq rule | N/A | |
| 2021-11-24 17:01 EST | News | Warning: CTIC is at high risk of performing badly | N/A | |
| 2021-10-02 09:05 EST | News | CTI Biopharma posts topline data from final analysis of Pacritinib COVID-19 trial | N/A | |
| 2021-08-25 15:29 EST | News | CTI BioPharma and DRI Healthcare Trust launch up to $135M debt and royalty transaction | N/A | |
| 2021-08-06 00:58 EST | News | CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-21 03:17 EST | News | FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA | N/A | |
| 2021-07-21 03:17 EST | News | CTI BioPharma EPS misses by $0.02 | N/A | |
| 2021-07-21 03:17 EST | News | CTI Biopharma net loss widens on R&D expenses, preparations for drug launch | N/A | |
| 2021-07-21 03:17 EST | News | CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q1 2021 Results - Earnings Call Transcript | N/A | |
| 2021-05-07 06:28 EST | News | CTI BioPharma initiated buy at Stifel; cites potential in myelofibrosis | N/A | |
| 2021-04-01 14:32 EST | News | CTI BioPharma secures $51M capital raise | N/A | |
| 2021-03-31 19:19 EST | News | CTI Biopharma completes rolling NDA submission of pacritinib in bone marrow cancer | N/A | |
| 2021-03-31 19:18 EST | News | CTI BioPharma down 11% on proposing public offering | N/A | |
| 2021-03-23 01:14 EST | News | CTI Bio announces peer-reviewed Phase 1 results for pacritinib in graft-versus-host disease | N/A | |
| 2021-03-18 20:38 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-18 17:00 EST | News | CTI BioPharma (CTIC) Investor Presentation - Slideshow | N/A | |
About CTI BioPharma Corp (CTIC):
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
General
- Name CTI BioPharma Corp
- Symbol CTIC
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 25
- Last Split Factor1:10
- Last Split Date2017-01-03
- Fiscal Year EndDecember
- IPO Date1997-03-21
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.ctibiopharma.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 87.01
- Price/Book (Most Recent Quarter) 5.32
- Enterprise Value Revenue 74.98
- Enterprise Value EBITDA 0.08
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.94
- Next Year EPS Estimate -$0.60
- Next Quarter EPS Estimate -$0.16
- Return on Assets -39%
- Return on Equity -125%
- Earnings Per Share -$0.62
- Revenue Per Share $0
- Gross Profit 3.35 million
- Quarterly Earnings Growth 216.6%
View More
Highlights
- Market Capitalization 246.79 million
- EBITDA -34066000
- Analyst Target Price $7.7
- Book Value Per Share $0.64
View More
Share Statistics
- Shares Outstanding 75.47 million
- Shares Float 52.45 million
- % Held by Insiders 26%
- % Held by Institutions 56.82%
- Shares Short 487801
- Shares Short Prior Month 377635
- Short Ratio 0.66
- Short % of Float 1%
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 0.81
- 52 Week High $4.03
- 52 Week Low $0.79
- 50 Day Moving Average 3.32
- 200 Day Moving Average 2.97
View More
Dividends
- Dividend Date 2017-01-03
- ExDividend Date N/A
- Dividend Yield 0%
View More
CTI BioPharma Corp (CTIC) Dividend Calendar:
CTIC's last dividend payment was made to shareholders on January 3, 2017.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
CTI BioPharma Corp (CTIC) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $N/A | -$0.20 | -$0.16 | -25% |
| 2020-09-30 | 2020-11-10 | $N/A | -$0.15 | -$0.15 | 2.15% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.19 | -$0.12 | -54.1% |
| 2020-03-31 | 2020-05-07 | $N/A | -$0.20 | -$0.13 | -53.85% |
| 2019-12-31 | 2020-03-12 | $N/A | -$0.14 | -$0.23 | 37.78% |
| 2019-09-30 | 2019-11-04 | $2.29 million | -$0.17 | -$0.23 | 26.09% |
| 2019-06-30 | 2019-08-01 | $416000 | -$0.19 | -$0.19 | 0% |
| 2019-03-31 | 2019-05-02 | $640000 | -$0.19 | -$0.21 | 9.52% |
| 2018-12-31 | 2019-03-13 | $14.48 million | $0.01 | -$0.27 | 103.7% |
| 2018-09-30 | 2018-11-01 | $723000 | -$0.26 | -$0.22 | -16.85% |
| 2018-06-30 | 2018-08-02 | $613000 | -$0.20 | -$0.23 | 13.04% |
| 2018-03-31 | 2018-05-03 | $10.48 million | -$0.08 | -$0.10 | 15.79% |
| 2017-12-31 | 2018-03-07 | $462000 | -$0.33 | -$0.28 | -17.86% |
| 2017-09-30 | 2017-11-06 | $1.71 million | -$0.28 | -$0.32 | 12.5% |
| 2017-06-30 | 2017-08-04 | $22.23 million | $0.03 | ||
| 2017-03-31 | 2017-05-03 | $754000 | -$0.71 | -$0.70 | -1.43% |
| 2016-12-31 | 2017-03-02 | $9.14 million | -$0.23 | -$0.65 | 64.62% |
| 2016-09-30 | 2016-11-08 | $4.43 million | -$1.00 | -$0.70 | -42.86% |
| 2016-06-30 | 2016-08-04 | $7.36 million | -$0.70 | -$0.90 | 22.22% |
| 2016-03-31 | 2016-05-10 | $36.48 million | $0.10 | -$0.40 | 125% |
| 2015-12-31 | 2016-02-16 | $11.32 million | -$1.30 | -$1.80 | 27.78% |
| 2015-09-30 | 2015-11-05 | $964000 | -$1.90 | -$1.23 | -54.47% |
| 2015-06-30 | 2015-08-06 | $1.1 million | -$1.90 | -$0.95 | -100% |
| 2015-03-31 | 2015-05-06 | $2.73 million | -$1.60 | -$1.40 | -14.29% |
| 2014-12-31 | 2015-03-12 | $17.79 million | -$1.40 | -$1.80 | 22.22% |
| 2014-09-30 | 2014-10-29 | $39.53 million | $0.03 | -$0.03 | 200% |
| 2014-06-30 | 2014-08-04 | $1.34 million | -$1.90 | -$1.27 | -49.61% |
| 2014-03-31 | 2014-04-29 | $1.41 million | -$2.00 | -$1.67 | -19.76% |
| 2013-12-31 | 2014-03-04 | $32.88 million | $0.80 | -$1.57 | 150.96% |
| 2013-09-30 | 2013-10-30 | $362000 | -$2.00 | -$1.65 | -21.21% |
| 2013-06-30 | 2013-07-31 | $306000 | -$1.70 | -$1.70 | 0% |
| 2013-03-31 | 2013-05-02 | $1.13 million | -$1.80 | -$4.40 | 59.09% |
| 2012-12-31 | 2013-02-28 | $N/A | -$1.90 | -$2.00 | 5% |
| 2012-09-30 | 2012-11-01 | $N/A | -$3.70 | -$4.10 | 9.76% |
| 2012-06-30 | 2012-08-01 | $N/A | -$13.78 | ||
| 2012-03-31 | 2012-04-20 | $N/A | -$4.50 | -$5.00 | 10% |
| 2011-12-31 | 2012-03-08 | $N/A | -$4.50 | -$4.00 | -12.5% |
| 2011-09-30 | 2011-10-25 | $319000 | -$8.00 | -$4.50 | -77.78% |
| 2011-06-30 | 2011-07-28 | $-319000 | -$7.00 | -$6.00 | -16.67% |
| 2011-03-31 | 2011-04-27 | $N/A | -$18.00 | -$6.00 | -200% |
| 2010-12-31 | 2011-02-16 | $N/A | -$12.00 | -$6.00 | -100% |
| 2010-09-30 | 2010-10-28 | $20000 | -$6.00 | -$18.00 | 66.67% |
| 2010-06-30 | 2010-08-05 | $299000 | -$24.00 | -$6.00 | -300% |
| 2010-03-31 | 2010-04-28 | $20000 | -$21.00 | -$15.00 | -40% |
| 2009-12-31 | 2010-02-11 | $20000 | -$15.00 | -$9.00 | -66.67% |
| 2009-09-30 | 2009-11-05 | $20000 | -$27.79 | ||
| 2009-06-30 | 2009-08-06 | $20000 | -$18.00 | -$15.00 | -20% |
| 2009-03-31 | 2009-05-07 | $20000 | -$15.00 | -$94.50 | 84.13% |
| 2008-12-31 | 2009-03-16 | $2.55 million | -$156.00 | -$489.00 | 68.1% |
| 2008-09-30 | 2008-11-07 | $2.6 million | -$849.00 | -$990.00 | 14.24% |
| 2008-06-30 | 2008-08-18 | $2.89 million | -$1,560.00 | -$900.00 | -73.33% |
| 2008-03-31 | 2008-05-08 | $3.39 million | -$2,310.00 | -$1,270.00 | -81.89% |
| 2007-12-31 | 2008-03-13 | $67000 | -$2,220.00 | -$1,570.00 | -41.4% |
| 2007-09-30 | 2007-11-08 | $20000 | -$1,950.00 | -$1,890.00 | -3.17% |
| 2007-06-30 | 2007-08-08 | $20000 | -$1,950.00 | -$1,900.00 | -2.63% |
| 2007-03-31 | 2007-05-02 | $20000 | -$2,280.00 | -$1,560.00 | -46.15% |
| 2006-12-31 | 2007-03-15 | $20000 | -$3,000.00 | -$2,240.00 | -33.93% |
| 2006-09-30 | 2006-11-07 | $20000 | -$3,000.00 | -$2,760.00 | -8.7% |
| 2006-06-30 | 2006-08-08 | $20000 | -$2,400.00 | -$2,940.00 | 18.37% |
| 2006-03-31 | 2006-05-04 | $20000 | -$7,080.00 | -$3,540.00 | -100% |
| 2005-12-31 | 2006-03-09 | $1.19 million | -$3,240.00 | -$1,960.00 | -65.31% |
| 2005-09-30 | 2005-11-14 | $1.29 million | -$1,560.00 | -$6,000.00 | 74% |
| 2005-06-30 | 2005-08-09 | $7.47 million | -$6,840.00 | -$6,420.00 | -6.54% |
| 2005-03-31 | 2005-05-02 | $6.14 million | -$7,440.00 | -$6,400.00 | -16.25% |
| 2004-12-31 | 2005-02-28 | $8.13 million | -$8,640.00 | -$6,466.67 | -33.61% |
| 2004-09-30 | 2004-11-09 | $8.67 million | -$7,440.00 | -$6,020.00 | -23.59% |
| 2004-06-30 | 2004-07-27 | $8.3 million | -$9,000.00 | -$8,057.14 | -11.7% |
| 2004-03-31 | 2004-05-06 | $4.5 million | -$11,640.00 | -$8,232.00 | -41.4% |
| 2003-12-31 | 2004-02-11 | $7.22 million | -$13,080.00 | -$10,650.00 | -22.82% |
| 2003-09-30 | 2003-10-21 | $6.54 million | -$11,520.00 | -$10,360.00 | -11.2% |
| 2003-06-30 | 2003-07-24 | $6.13 million | -$11,160.00 | -$7,960.00 | -40.2% |
| 2003-03-31 | 2003-04-22 | $4.88 million | -$11,040.00 | -$8,280.00 | -33.33% |
| 2002-12-31 | 2003-02-20 | $7.96 million | -$9,120.00 | -$10,980.00 | 16.94% |
| 2002-09-30 | 2002-10-24 | $4.41 million | -$11,160.00 | -$9,548.57 | -16.88% |
| 2002-06-30 | 2002-07-24 | $2.85 million | -$9,240.00 | -$8,088.00 | -14.24% |
| 2002-03-31 | 2002-04-24 | $1.68 million | -$8,040.00 | -$7,536.00 | -6.69% |
| 2001-12-31 | 2002-02-20 | $2.42 million | -$11,400.00 | -$7,480.00 | -52.41% |
| 2001-09-30 | 2001-10-22 | $1 million | -$7,680.00 | -$6,068.57 | -26.55% |
| 2001-06-30 | 2001-07-26 | $1.89 million | -$5,640.00 | -$5,620.00 | -0.36% |
| 2001-03-31 | 2001-04-26 | $929000 | -$4,200.00 | -$5,480.00 | 23.36% |
| 2000-12-31 | 2001-02-15 | $502000 | -$5,640.00 | -$4,200.00 | -34.29% |
| 2000-09-30 | 2000-10-19 | $N/A | -$6,600.00 | -$5,820.00 | -13.4% |
| 2000-06-30 | 2000-08-14 | $N/A | -$5,760.00 | -$5,880.00 | 2.04% |
| 2000-03-31 | 2000-05-16 | $N/A | -$6,840.00 | -$3,360.00 | -103.57% |
| 1999-09-30 | 1999-09-30 | -$7,682.59 | |||
| 1999-06-30 | 1999-06-30 | -$7,662.72 | |||
| 1999-03-31 | 1999-03-31 | -$6,226.45 | |||
| 1998-09-30 | 1998-10-30 | -$4,320.00 | -$8,040.00 | 46.27% | |
| 1998-06-30 | 1998-08-03 | -$4,080.00 | -$7,200.00 | 43.33% | |
| 1998-03-31 | 1998-03-31 | -$4,836.86 | |||
| 1997-12-31 | 1998-02-23 | -$6,720.00 | -$6,240.00 | -7.69% | |
| 1997-09-30 | 1997-11-13 | -$3,960.00 | -$6,280.00 | 36.94% | |
| 1997-06-30 | 1997-08-15 | -$4,440.00 | -$5,000.00 | 11.2% | |
| 1997-03-31 | 1997-05-16 | -$6,840.00 | -$6,240.00 | -9.62% |
CTI BioPharma Corp (CTIC) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
CTI BioPharma Corp (CTIC) Chart:
CTI BioPharma Corp (CTIC) News:
Below you will find a list of latest news for CTI BioPharma Corp (CTIC) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
CTI BioPharma Corp (CTIC) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-01-17 | 1 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-01-17 | 2 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-01-17 | 3 | 5.7 | CALL | 0 | 0 | 100.99 | TRUE | 0 | 0 |
| 2025-01-17 | 4 | 2.6 | CALL | 0 | 6 | 74.19 | TRUE | 0 | 0 |
| 2025-01-17 | 5 | 3.3 | CALL | 0 | 3 | 57.39 | TRUE | 0 | 0 |
| 2025-01-17 | 7 | 2.05 | CALL | 0 | 266 | 0 | TRUE | 0 | 0 |
| 2025-01-17 | 10 | 0.05 | CALL | 0 | 486 | 2.1 | FALSE | 0 | 0 |
| 2025-01-17 | 12 | 0.05 | CALL | 0 | 59 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 15 | 0.15 | CALL | 0 | 3 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 17 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 1 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 2 | 0.4 | PUT | 0 | 90 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 3 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 4 | 1.12 | PUT | 0 | 10 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 5 | 0.1 | PUT | 0 | 19 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 7 | 0.15 | PUT | 0 | 269 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 10 | 1.1 | PUT | 0 | 1 | 14.22 | TRUE | 0 | 0 |
| 2025-01-17 | 12 | 3 | PUT | 0 | 10 | 32.37 | TRUE | 0 | 0 |
| 2025-01-17 | 15 | 0 | PUT | 0 | 0 | 65.51 | TRUE | 0 | 0 |
| 2025-01-17 | 17 | 8.6 | PUT | 0 | 1 | 63.25 | TRUE | 0 | 0 |
Latest CTIC Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 144 | $5.145 |
| Jun 13, 2022 7:59 PM EST | 126 | $5.145 |
| Jun 13, 2022 7:59 PM EST | 144 | $5.145 |
| Jun 13, 2022 7:59 PM EST | 100 | $5.145 |
| Jun 13, 2022 7:59 PM EST | 102 | $5.145 |
CTI BioPharma Corp (CTIC) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129320000046/0000891293-20-000046-index.htm |
| 2018-02-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000039/0000891293-18-000039-index.htm |
| 2018-03-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000042/0000891293-18-000042-index.htm |
| 2018-03-07 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/891293/000089129318000043/0000891293-18-000043-index.htm |
| 2018-03-21 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/891293/000089129318000046/0000891293-18-000046-index.htm |
| 2018-03-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000048/0000891293-18-000048-index.htm |
| 2018-03-30 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/891293/000089129318000051/0000891293-18-000051-index.htm |
| 2018-05-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000054/0000891293-18-000054-index.htm |
| 2018-05-03 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/891293/000089129318000055/0000891293-18-000055-index.htm |
| 2018-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129318000056/0000891293-18-000056-index.htm |
| 2018-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129318000057/0000891293-18-000057-index.htm |
| 2018-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129318000058/0000891293-18-000058-index.htm |
| 2018-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129318000059/0000891293-18-000059-index.htm |
| 2018-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129318000060/0000891293-18-000060-index.htm |
| 2018-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129318000061/0000891293-18-000061-index.htm |
| 2018-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129318000062/0000891293-18-000062-index.htm |
| 2018-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129318000063/0000891293-18-000063-index.htm |
| 2018-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129318000064/0000891293-18-000064-index.htm |
| 2018-05-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000066/0000891293-18-000066-index.htm |
| 2018-05-22 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/891293/000089129318000069/0000891293-18-000069-index.htm |
| 2018-05-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000071/0000891293-18-000071-index.htm |
| 2018-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129318000072/0000891293-18-000072-index.htm |
| 2018-07-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000074/0000891293-18-000074-index.htm |
| 2018-08-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000077/0000891293-18-000077-index.htm |
| 2018-08-03 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/891293/000089129318000078/0000891293-18-000078-index.htm |
| 2018-08-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000080/0000891293-18-000080-index.htm |
| 2018-08-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000082/0000891293-18-000082-index.htm |
| 2018-09-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000084/0000891293-18-000084-index.htm |
| 2018-09-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129318000085/0000891293-18-000085-index.htm |
| 2018-09-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129318000086/0000891293-18-000086-index.htm |
| 2018-09-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129318000087/0000891293-18-000087-index.htm |
| 2018-09-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129318000088/0000891293-18-000088-index.htm |
| 2018-09-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000090/0000891293-18-000090-index.htm |
| 2018-11-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000092/0000891293-18-000092-index.htm |
| 2018-11-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/891293/000089129318000095/0000891293-18-000095-index.htm |
| 2018-11-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000097/0000891293-18-000097-index.htm |
| 2018-12-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000099/0000891293-18-000099-index.htm |
| 2018-12-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000101/0000891293-18-000101-index.htm |
| 2018-12-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129318000103/0000891293-18-000103-index.htm |
| 2019-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129319000002/0000891293-19-000002-index.htm |
| 2019-01-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129319000004/0000891293-19-000004-index.htm |
| 2019-02-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129319000006/0000891293-19-000006-index.htm |
| 2019-02-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129319000008/0000891293-19-000008-index.htm |
| 2019-02-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129319000009/0000891293-19-000009-index.htm |
| 2019-02-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129319000010/0000891293-19-000010-index.htm |
| 2019-02-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129319000012/0000891293-19-000012-index.htm |
| 2019-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129319000014/0000891293-19-000014-index.htm |
| 2019-03-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129319000018/0000891293-19-000018-index.htm |
| 2019-03-13 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/891293/000089129319000021/0000891293-19-000021-index.htm |
| 2019-03-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129319000023/0000891293-19-000023-index.htm |
| 2019-03-25 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/891293/000089129319000025/0000891293-19-000025-index.htm |
| 2019-04-04 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/891293/000089129319000028/0000891293-19-000028-index.htm |
| 2019-04-04 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/891293/000089129319000029/0000891293-19-000029-index.htm |
| 2019-04-17 | DEFR14A | Revised definitive proxy soliciting materials | https://www.sec.gov/Archives/edgar/data/891293/000089129319000031/0000891293-19-000031-index.htm |
| 2019-04-22 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/891293/000089129319000033/0000891293-19-000033-index.htm |
| 2019-05-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129319000038/0000891293-19-000038-index.htm |
| 2019-05-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/891293/000089129319000039/0000891293-19-000039-index.htm |
| 2019-05-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129319000041/0000891293-19-000041-index.htm |
| 2019-05-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129319000042/0000891293-19-000042-index.htm |
| 2019-05-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129319000043/0000891293-19-000043-index.htm |
| 2019-05-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129319000044/0000891293-19-000044-index.htm |
| 2019-05-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129319000045/0000891293-19-000045-index.htm |
| 2019-05-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129319000046/0000891293-19-000046-index.htm |
| 2019-05-23 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/891293/000089129319000048/0000891293-19-000048-index.htm |
| 2019-06-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129319000050/0000891293-19-000050-index.htm |
| 2019-07-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129319000053/0000891293-19-000053-index.htm |
| 2019-08-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129319000056/0000891293-19-000056-index.htm |
| 2019-08-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/891293/000089129319000058/0000891293-19-000058-index.htm |
| 2019-10-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129319000060/0000891293-19-000060-index.htm |
| 2019-11-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129319000064/0000891293-19-000064-index.htm |
| 2019-11-04 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/891293/000089129319000065/0000891293-19-000065-index.htm |
| 2020-02-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129320000002/0000891293-20-000002-index.htm |
| 2020-02-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129320000004/0000891293-20-000004-index.htm |
| 2020-03-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129320000006/0000891293-20-000006-index.htm |
| 2020-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129320000010/0000891293-20-000010-index.htm |
| 2020-03-13 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/891293/000089129320000012/0000891293-20-000012-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129320000013/0000891293-20-000013-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129320000014/0000891293-20-000014-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129320000015/0000891293-20-000015-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129320000016/0000891293-20-000016-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129320000017/0000891293-20-000017-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129320000018/0000891293-20-000018-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129320000019/0000891293-20-000019-index.htm |
| 2020-04-13 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/891293/000089129320000021/0000891293-20-000021-index.htm |
| 2020-04-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129320000023/0000891293-20-000023-index.htm |
| 2020-04-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129320000029/0000891293-20-000029-index.htm |
| 2020-04-23 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/891293/000089129320000031/0000891293-20-000031-index.htm |
| 2020-04-23 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/891293/000089129320000033/0000891293-20-000033-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129320000039/0000891293-20-000039-index.htm |
| 2020-05-15 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/891293/000089129320000041/0000891293-20-000041-index.htm |
| 2020-06-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129320000043/0000891293-20-000043-index.htm |
| 2020-06-19 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/891293/000089129320000045/0000891293-20-000045-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000089129320000046/0000891293-20-000046-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000089129320000049/0000891293-20-000049-index.htm |
| 2020-08-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/891293/000089129320000051/0000891293-20-000051-index.htm |
| 2020-10-02 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/891293/000091957420006094/0000919574-20-006094-index.htm |
| 2018-02-12 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/891293/000092189518000517/0000921895-18-000517-index.htm |
| 2018-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000092189518000533/0000921895-18-000533-index.htm |
| 2018-05-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000092189518001774/0000921895-18-001774-index.htm |
| 2019-05-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000092189519001579/0000921895-19-001579-index.htm |
| 2020-02-04 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/891293/000092189520000244/0000921895-20-000244-index.htm |
| 2020-03-04 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/891293/000092189520000649/0000921895-20-000649-index.htm |
| 2020-03-04 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000092189520000653/0000921895-20-000653-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000092189520000654/0000921895-20-000654-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/891293/000093583619000108/0000935836-19-000108-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/891293/000093583620000111/0000935836-20-000111-index.htm |
| 2020-03-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/891293/000094787120000206/0000947871-20-000206-index.htm |
| 2020-03-10 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/891293/000094787120000207/0000947871-20-000207-index.htm |
| 2018-02-20 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/891293/000107261318000153/0001072613-18-000153-index.htm |
| 2020-02-13 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/891293/000107261320000085/0001072613-20-000085-index.htm |
| 2020-03-12 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/891293/000107261320000128/0001072613-20-000128-index.htm |
| 2018-11-01 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/891293/000119312518315801/0001193125-18-315801-index.htm |
| 2018-11-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000119312518315813/0001193125-18-315813-index.htm |
| 2019-11-15 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/891293/000119312519293416/0001193125-19-293416-index.htm |
| 2019-11-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000119312519293424/0001193125-19-293424-index.htm |
| 2019-12-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000119312519307531/0001193125-19-307531-index.htm |
| 2020-02-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000119312520036662/0001193125-20-036662-index.htm |
| 2020-02-14 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/891293/000119312520036807/0001193125-20-036807-index.htm |
| 2020-09-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/891293/000119312520257884/0001193125-20-257884-index.htm |
| 2019-03-19 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/891293/999999999719001419/9999999997-19-001419-index.htm |
| 2019-10-23 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/891293/999999999719007336/9999999997-19-007336-index.htm |
CTI BioPharma Corp (CTIC) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of CTI BioPharma Corp (CTIC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 26%Institutional Ownership: 5682%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-02-09 | PARTNERS L P/IL BVF | 10% Share Holder | Sell | 3,566,549.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/891293/000092189518000533/0000921895-18-000533-index.htm | ||
| 2018-02-09 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 699,225.00 | 3.00 | 2,097,675.00 | 1,295,582.00 | https://www.sec.gov/Archives/edgar/data/891293/000092189518000533/0000921895-18-000533-index.htm |
| 2018-02-09 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 2,109,280.00 | 3.00 | 6,327,840.00 | 2,109,280.00 | https://www.sec.gov/Archives/edgar/data/891293/000092189518000533/0000921895-18-000533-index.htm |
| 2018-02-09 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 3,041,120.00 | 3.00 | 9,123,360.00 | 3,041,120.00 | https://www.sec.gov/Archives/edgar/data/891293/000092189518000533/0000921895-18-000533-index.htm |
| 2018-06-30 | BRUCE J. SEELEY | EVP, Chief Operating Officer | Buy | 500.00 | 2.30 | 1,147.50 | 31,500.00 | https://www.sec.gov/Archives/edgar/data/891293/000089129318000072/0000891293-18-000072-index.htm |
| 2018-12-31 | BRUCE J. SEELEY | EVP, Chief Operating Officer | Buy | 500.00 | 0.62 | 311.80 | 32,000.00 | https://www.sec.gov/Archives/edgar/data/891293/000089129319000002/0000891293-19-000002-index.htm |
| 2020-06-30 | BRUCE J. SEELEY | EVP, Chief Operating Officer | Buy | 500.00 | 0.99 | 493.00 | 32,500.00 | https://www.sec.gov/Archives/edgar/data/891293/000089129320000046/0000891293-20-000046-index.htm |
| 2018-02-09 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 483,708.00 | 3.00 | 1,451,124.00 | 483,708.00 | https://www.sec.gov/Archives/edgar/data/891293/000092189518000533/0000921895-18-000533-index.htm |
| 2018-02-09 | PARTNERS L P/IL BVF | 10% Share Holder | Sell | 1,487,294.00 | 596,357.00 | https://www.sec.gov/Archives/edgar/data/891293/000092189518000533/0000921895-18-000533-index.htm |